trial

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

NCTId NCT00917293
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 53 (actual)
Sponsored by Medicure
Primary completion 2012-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
53 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2009-05
Primary completion
2012-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pyridoxal 5'-Phosphate

Sponsors

MedicureLead Sponsor

Investigators

1
Gary Remington, MD PhD FRCPCPrincipal Investigator

Sites

4 total
Victoria, CanadaToronto, CanadaWindsor, CanadaChennai, India

Linked catalysts

1
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyski — primary completion2012-08

Facts & assertions

4 sourced
Enrollment
53
Phase
PHASE2
Primary Completion Date
2012-08
Status
TERMINATED
relationships
The graph out of here
drug
Pyridoxal 5'-Phosphate
drug
lead_sponsor
Medicure
company
indication
Tardive Dyskinesia
indication
Schizophrenia
indication
Tardive Dyskinesia
indication
investigator
Gary Remington, MD PhD FRCPC
person